Announcement
10.02.2012


NeuroSearch A/S (NEUR) has decided to conduct the Annual General Meeting on

Tuesday, 10 April 2012

This changes the previously announced date which was 25 April 2012.

Submission of motions
Shareholders who wish to submit motions for the Annual General Meeting must do
so in writing to the Board of Director no later than Tuesday, 28 February 2012.
Please submit either electronically to [email protected] or by ordinary
mail to the company's postal address. Please mark 'Annual General Meeting'.

Patrik Dahlen
CEO

Contact person:
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097

About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on
NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is to complete the development and
subsequently to market Huntexil®, a unique drug in clinical Phase III for the
treatment of the motor symptoms of Huntington’s disease.
As a consequence of the restructuring of NeuroSearch that was announced 27
September 2011, the company also has a portfolio of assets for outlicensing or
divestment.

Fonds.02-12 - Annual General Meeting - new date - uk.pdf